You are here: Industry Insights > Sobi

News List

NICE recommends Sobi’s Kineret for first-line use in Still’s disease pharmatimes
March 31, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Sobi’s Kineret for the first-line treatment of the rare inflammatory disorder Still’s disease.
First Patient Dosed in Avatrombopag Study ITP in Children americanpharmaceuticalreview
March 22, 2021
Swedish Orphan Biovitrum announced the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist (TPO-RA), for treatment of immune thrombocytopenia (ITP) in pediatric patients.
USFDA grants FTD to efanesoctocog alfa for hemophilia A treatment pharmaceutical-business-review
February 25, 2021
The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.
Sobi launches thrombocytopenia drug Doptelet in EU pharmatimes
November 06, 2020
Sobi (Swedish Orphan Biovitrum) has launched Doptelet (avatrombopag) in Europe, which is approved for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD).
Apellis enters drug development and commercialisation deal with Sobi pharmaceutical-technology
October 29, 2020
Apellis Pharmaceuticals has entered into a strategic collaboration with Swedish Orphan Biovitrum (Sobi) to fast-track the advancement of systemic pegcetacoplan to treat multiple rare diseases with high unmet need.
Sobi to refile Gamifant following CHMP rejection pharmatimes
July 28, 2020
Sobi has announced its intent to file for a re-examination of Gamifant (emapalumab) in Europe following negative opinion by the European Medicines Agency's human medicines committee.
Sobi releases new haemophilia treatment report pharmaceutical-technology
April 20, 2020
Biopharmaceutical firm Sobi has released the 2020 Haemophilia Index, a report that analyses the quality of life of patients treated for haemophilia in Europe.
AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi worldpharmanews
August 26, 2019
AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of...
Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology expressbpd
June 14, 2019
The drug-maker said that it would buy a newly established company owning the drug candidate for the treatment of primary haemophagocytic lymphohistiocytosis (HLH)
Sobi to acquire emapalumab drug from Novimmune americanpharmaceuticalreview
June 14, 2019
Swedish Orphan Biovitrum (Sobi) has agreed to buy a newly established firm from Novimmune for a consideration of SEK4,897m ($517.9m).

Previous page 1 2 Next page